JP6777626B2 - セリネクソールの多形体 - Google Patents

セリネクソールの多形体 Download PDF

Info

Publication number
JP6777626B2
JP6777626B2 JP2017508087A JP2017508087A JP6777626B2 JP 6777626 B2 JP6777626 B2 JP 6777626B2 JP 2017508087 A JP2017508087 A JP 2017508087A JP 2017508087 A JP2017508087 A JP 2017508087A JP 6777626 B2 JP6777626 B2 JP 6777626B2
Authority
JP
Japan
Prior art keywords
structural formula
single crystal
compound
crystal form
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527549A (ja
JP2017527549A5 (enExample
Inventor
クリントン オースタッド，ブライアン
クリントン オースタッド，ブライアン
ロー，デービッド，ジー．
Original Assignee
カリオファーム セラピューティクス，インコーポレイテッド
カリオファーム セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリオファーム セラピューティクス，インコーポレイテッド, カリオファーム セラピューティクス，インコーポレイテッド filed Critical カリオファーム セラピューティクス，インコーポレイテッド
Publication of JP2017527549A publication Critical patent/JP2017527549A/ja
Publication of JP2017527549A5 publication Critical patent/JP2017527549A5/ja
Application granted granted Critical
Publication of JP6777626B2 publication Critical patent/JP6777626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017508087A 2014-08-15 2015-08-14 セリネクソールの多形体 Active JP6777626B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
US62/038,069 2014-08-15
PCT/US2015/045395 WO2016025904A1 (en) 2014-08-15 2015-08-14 Polymorphs of selinexor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020093874A Division JP7218323B2 (ja) 2014-08-15 2020-05-29 セリネクソールの多形体

Publications (3)

Publication Number Publication Date
JP2017527549A JP2017527549A (ja) 2017-09-21
JP2017527549A5 JP2017527549A5 (enExample) 2018-09-27
JP6777626B2 true JP6777626B2 (ja) 2020-10-28

Family

ID=53969460

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017508087A Active JP6777626B2 (ja) 2014-08-15 2015-08-14 セリネクソールの多形体
JP2020093874A Active JP7218323B2 (ja) 2014-08-15 2020-05-29 セリネクソールの多形体
JP2023009361A Active JP7558310B2 (ja) 2014-08-15 2023-01-25 セリネクソールの多形体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020093874A Active JP7218323B2 (ja) 2014-08-15 2020-05-29 セリネクソールの多形体
JP2023009361A Active JP7558310B2 (ja) 2014-08-15 2023-01-25 セリネクソールの多形体

Country Status (18)

Country Link
US (6) US10519139B2 (enExample)
EP (2) EP4112615A1 (enExample)
JP (3) JP6777626B2 (enExample)
KR (1) KR102608259B1 (enExample)
CN (3) CN111481553B (enExample)
AU (4) AU2015301484B2 (enExample)
CA (1) CA2957266A1 (enExample)
CO (1) CO2017001884A2 (enExample)
DK (1) DK3180331T3 (enExample)
EA (1) EA201790384A1 (enExample)
ES (1) ES2926377T3 (enExample)
IL (1) IL250328B (enExample)
MA (1) MA40254B1 (enExample)
MX (2) MX388170B (enExample)
SG (2) SG11201700789SA (enExample)
UA (1) UA123535C2 (enExample)
WO (1) WO2016025904A1 (enExample)
ZA (1) ZA201700880B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143144A (ja) * 2014-08-15 2020-09-10 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
US9096543B2 (en) 2012-05-09 2015-08-04 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
CN110386919B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
CA3130107A1 (en) * 2019-03-20 2020-09-24 Johnson Matthey Public Limited Company Co-crystal forms of selinexor
MA55808A (fr) * 2019-05-01 2022-03-09 Karyopharm Therapeutics Inc Procédé de préparation d'inhibiteurs de xpo1 et intermédiaires destinés à être utilisés dans la préparation d'inhibiteurs de xpo1
EP3968987A4 (en) * 2019-05-16 2022-10-26 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2023122014A1 (en) * 2021-12-20 2023-06-29 Raytheon Technologies Corporation Particle enhancement of ceramic matrix composites, method of manufacture thereof and articles comprising the same
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
EP0793653A1 (en) 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
JP4064462B2 (ja) 1996-04-04 2008-03-19 塩野義製薬株式会社 セフェム化合物及び該化合物を含有する医薬
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
PT913392E (pt) 1996-04-25 2003-11-28 Nissan Chemical Ind Ltd Derivados de etileno e agentes pesticidas
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
JP2004509941A (ja) 2000-09-29 2004-04-02 プロリフィクス　リミテッド Ｈｄａｃインヒビターとしてのアミド結合を含むカルバミン酸化合物
BR0212510A (pt) 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
JP4101852B2 (ja) 2004-05-26 2008-06-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物
BRPI0515015A (pt) 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US8637559B2 (en) * 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
WO2007118137A1 (en) 2006-04-07 2007-10-18 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
JP4999923B2 (ja) 2006-06-13 2012-08-15 中国科学院上海薬物研究所 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物
CA2658925C (en) 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CA2662112A1 (en) 2006-09-05 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2451280A4 (en) 2009-07-09 2012-12-26 Crescendo Therapeutics Llc METHOD FOR WOUND HEALING AND SCALING MODULATION
WO2011069039A1 (en) 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
JP5816635B2 (ja) 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
UA117902C2 (uk) 2011-07-29 2018-10-25 Каріофарм Терапеутікс, Інк. Модулятори ядерного транспорту та їхнє застосування
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
US9096543B2 (en) 2012-05-09 2015-08-04 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
CN110386919B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) * 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
JP6805137B2 (ja) 2014-07-11 2020-12-23 アンセルム（アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 血液学的癌を診断するための方法
CA2954189A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
SG11201700789SA (en) 2014-08-15 2017-02-27 Karyopharm Therapeutics Inc Polymorphs of selinexor
US10777299B2 (en) 2015-08-28 2020-09-15 The Trustees Of Columbia University In The City Of New York Systems and methods for matching oncology signatures
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
EP3946339A1 (en) 2019-03-27 2022-02-09 Karyopharm Therapeutics Inc. Biomarkers for selinexor
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
EP4069546B1 (en) 2019-12-06 2024-11-06 BAE SYSTEMS plc Light source
US20230391754A1 (en) 2020-10-21 2023-12-07 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020143144A (ja) * 2014-08-15 2020-09-10 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体
JP7218323B2 (ja) 2014-08-15 2023-02-06 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体

Also Published As

Publication number Publication date
JP7218323B2 (ja) 2023-02-06
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
DK3180331T3 (da) 2022-09-12
US11746102B2 (en) 2023-09-05
US20240208943A1 (en) 2024-06-27
EA201790384A1 (ru) 2017-08-31
JP2023052622A (ja) 2023-04-11
CN107072992A (zh) 2017-08-18
WO2016025904A1 (en) 2016-02-18
UA123535C2 (uk) 2021-04-21
CA2957266A1 (en) 2016-02-18
CN111484483A (zh) 2020-08-04
JP2020143144A (ja) 2020-09-10
CN111481553A (zh) 2020-08-04
US12371420B2 (en) 2025-07-29
US11078190B2 (en) 2021-08-03
MX2017002013A (es) 2017-05-12
JP2017527549A (ja) 2017-09-21
EP4112615A1 (en) 2023-01-04
US11753401B2 (en) 2023-09-12
KR102608259B1 (ko) 2023-11-29
AU2021286266B2 (en) 2024-02-01
AU2015301484B2 (en) 2020-02-20
AU2021286266A1 (en) 2022-01-06
US20220135545A1 (en) 2022-05-05
JP7558310B2 (ja) 2024-09-30
ZA201700880B (en) 2020-01-29
NZ728850A (en) 2024-03-22
CO2017001884A2 (es) 2017-07-19
KR20170043561A (ko) 2017-04-21
SG11201700789SA (en) 2017-02-27
US20230242517A1 (en) 2023-08-03
EP3180331B1 (en) 2022-06-08
MA40254A (fr) 2021-05-19
AU2020203246A1 (en) 2020-06-04
US20180215733A1 (en) 2018-08-02
IL250328A0 (en) 2017-03-30
CN107072992B (zh) 2020-03-10
CN111481553B (zh) 2023-09-01
ES2926377T3 (es) 2022-10-25
AU2015301484A1 (en) 2017-03-02
US11807629B2 (en) 2023-11-07
CN111484483B (zh) 2023-05-26
MA40254B1 (fr) 2022-09-30
MX2021014128A (es) 2022-01-04
IL250328B (en) 2022-05-01
EP3180331A1 (en) 2017-06-21
US20230242516A1 (en) 2023-08-03
US20200283419A1 (en) 2020-09-10
US10519139B2 (en) 2019-12-31
SG10201808624VA (en) 2018-11-29
MX388170B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
JP6777626B2 (ja) セリネクソールの多形体
KR102322794B1 (ko) 핵수송 조절인자 및 이의 용도
JP2018528196A (ja) 癌の治療のための（ｓ，ｅ）−３−（６−アミノピリジン−３−イル）−ｎ−（（５−（４−（３−フルオロ−３−メチルピロリジン−１−カルボニル）フェニル）−７−（４−フルオロフェニル）ベンゾフラン−２−イル）メチル）アクリルアミド
US20230391754A1 (en) Crystalline form of selinexor
HK40086113A (en) Compositions comprising one crystalline form of selinexor
HK40034639B (zh) 赛灵克斯的多晶型物
HK40034638B (en) Polymorphs of selinexor
WO2024102477A1 (en) Crystalline forms of eltanexor and process for preparing same
HK40034639A (en) Polymorphs of selinexor
HK1238240A1 (en) Polymorphs of selinexor
HK1238240B (en) Polymorphs of selinexor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201008

R150 Certificate of patent or registration of utility model

Ref document number: 6777626

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250